WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy
Saved in:
| Main Authors: | Vinod Kumar, Harbir Kohli, Raja Ramachandran |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924024616 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WCN25-4122 Rituximab in Primary Membranous Nephropathy- three years outcome
by: Prabjot Kaur Johal, et al.
Published: (2025-02-01) -
WCN25-2664 Low-dose versus Standard-dose cyclical Cyclophosphamide and Steroids in the treatment of Primary Membranous Nephropathy- a randomized controlled trial
by: Raja Ramachandran, et al.
Published: (2025-02-01) -
WCN25-1613 GLUCOCORTICOID TOXICITY INDEX IN MEMBRANOUS NEPHROPATHY AND PODOCYTOPATHIES IN ADULT: A PILOT STUDY
by: RAJESH KUMAR, et al.
Published: (2025-02-01) -
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01) -
WCN25-3929 RITUXIMAB VERSUS MODIFIED PONTICELLI REGIMEN IN THE MANAGEMENT OF PRIMARY MEMBRANOUS NEPHROPATHY IN A TERTIARY CARE CENTRE
by: VAISHNAVI KARNATI, et al.
Published: (2025-02-01)